Tag: Primary immunodeficiency

For individuals with primary immunodeficiency, intravenous immunoglobulin (IVIG) therapy is often a lifelong treatment administered every few weeks. So, **how many times can you get IVIG**? The answer is highly personalized and depends entirely on the underlying medical issue, the patient's response, and specific therapeutic goals, which can range from a single course to indefinite therapy.

For some conditions, Intravenous Immunoglobulin (IVIG) therapy can lead to significant and sustained improvement after a single dose. However, the notion that IVIG is a one-time treatment is a common misconception, as most people require multiple infusions over an extended period.

With an estimated prevalence of 1 in 1,200 individuals, Primary Immunodeficiencies (PI) affect a significant population [1.3.5]. For many, a key question is: **what is the immune globulin injection used for?** This therapy is a lifeline, providing essential antibodies to fight infection and regulate the immune system [1.6.5, 1.11.2].

Xembify is a 20% subcutaneous immune globulin (SCIG) replacement therapy approved for treating primary humoral immunodeficiency disease (PI) in patients aged 2 and older. For most patients, this treatment is administered at home following training from a healthcare professional. This guide will detail exactly how is Xembify administered, ensuring a safe and effective self-infusion process.

Immunoglobulin replacement therapy, such as Cuvitru, is the standard treatment for individuals with antibody deficiencies. This article explains how does Cuvitru work by providing the necessary antibodies to protect patients with primary immunodeficiency from recurrent bacterial and viral infections.